Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
about
Novel agents in the treatment of multiple myeloma: a review about the futureRole of endoplasmic reticulum stress in drug-induced toxicitySpotlight on ixazomib: potential in the treatment of multiple myelomaTouch and go: nuclear proteolysis in the regulation of metabolic genes and cancerUBXD Proteins: A Family of Proteins with Diverse Functions in CancerRecent advances and novel treatment paradigms in acute lymphocytic leukemiaCombined chemical-genetic approach identifies cytosolic HSP70 dependence in rhabdomyosarcomaDeubiquitinases (DUBs) and DUB inhibitors: a patent reviewThe next generation of novel therapies for the management of relapsed multiple myeloma.Dysregulation of the (immuno)proteasome pathway in malformations of cortical development.Targeting Cdc20 as a novel cancer therapeutic strategy.A Single α Helix Drives Extensive Remodeling of the Proteasome Lid and Completion of Regulatory Particle Assembly.Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance.Ubiquitin-Specific Proteases as Druggable Targets.Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells.UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3β/β-catenin pathwayTargeting plasma cells: are we any closer to a panacea for diseases of antibody-secreting cells?Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.Manipulation of viral infection by deubiquitinating enzymes: new players in host-virus interactions.Proteome complexity and the forces that drive proteome imbalance.Protein Quality Control Dysfunction in Cardiovascular Complications Induced by Anti-Cancer Drugs.3q26-29 Amplification in head and neck squamous cell carcinoma: a review of established and prospective oncogenes.Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.HSP70 dependence in rhabdomyosarcoma: Seed or soil?An assay for 26S proteasome activity based on fluorescence anisotropy measurements of dye-labeled protein substratesProteasome dysfunction triggers activation of SKN-1A/Nrf1 by the aspartic protease DDI-1.Bortezomib Alone and in Combination With Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death In Vitro and in Female Nude Mice.Proteasome inhibition by bortezomib: A left hook and a right punchMonitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA.Cancer stem cells don't waste their time cleaning-low proteasome activity, a marker for cancer stem cell function.It's all about talking: two-way communication between proteasomal and lysosomal degradation pathways via ubiquitin.The Biology of Aging and Cancer: A Brief Overview of Shared and Divergent Molecular Hallmarks.Low Neurotoxicity of ONX-0914 Supports the Idea of Specific Immunoproteasome Inhibition as a Side-Effect-Limiting, Therapeutic Strategy.Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells.Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity.In Vitro Metabolism of Oprozomib, an Oral Proteasome Inhibitor: Role of Epoxide Hydrolases and Cytochrome P450s.Nuclear ubiquitin C-terminal hydrolase L5 expression associates with increased patient survival in pancreatic ductal adenocarcinoma.Positioning of proteasome inhibitors in therapy of solid malignancies.
P2860
Q26745924-9FBFD1CC-03E2-4554-9560-3B3784353251Q26765518-FDD352DA-535B-4430-9D17-43B36A9A2545Q26774440-BC987F23-2976-4852-8169-8A184EE8EC18Q28068146-4D6E9EFB-CA89-4A65-AF6C-956A031542DDQ28069036-F2CDA28D-3ACC-4695-A868-1B6A980C2735Q28078076-A5EDC407-A31A-4A38-A5E3-6816B5AB6BD2Q28830095-1DB75403-6478-4A03-8ED7-3ECCD12C1C92Q28834608-78575DB8-CA93-476F-876B-191B3B5C38F9Q30248534-0F6A2EB0-425C-4143-9BF8-D89FFF7582D3Q30804418-96E4EC5C-22DD-4B52-9C3F-B13F0992FBF2Q35688708-4A23F846-B8FE-4D45-B730-FB275DFCB143Q36146766-54E7F809-DDDF-4718-935C-AC089E29D474Q36496096-C9607029-4F26-40F8-ADB2-D60E631B1545Q36509580-71BDFD5D-9B63-4F3A-95A4-2690ACD796DDQ37015742-55AD08B4-94C4-4CF7-AF68-172D22F0E8DDQ37046830-F13AEE59-2716-48F8-9021-D62674983134Q38728585-9D811EC6-B423-4D50-B815-A8422C819582Q38748855-1B836B75-AC69-45EE-8FB7-490D29B3E835Q38757895-EB5E2FC0-FEFD-4678-A14F-184FFE26C252Q38803414-04A7CAE4-FEF8-480F-B907-1F6B48F5165BQ38954697-669E25B3-2747-424A-B982-1318708F07F3Q39102231-7B64E7FE-795C-4620-940A-91E8C5FE1C65Q39186868-9FA63AA2-835E-4A49-A0C2-E9E718948313Q39234159-2B089CA7-A99C-42F2-83B8-4CA4FA47E826Q41607725-44950746-53BD-4548-B70F-CF807C93DAD1Q41664270-2386490A-955F-46ED-81DC-F26ABD49F49DQ41729079-C6881101-2930-4347-9ACA-BB3BC9C695FFQ41740375-DABCE78F-83B5-4DFB-B97F-CA585C89FE6DQ41932078-6137A80D-FD3E-4323-9306-CAC5E81D95E2Q42001818-91065660-028A-4386-A812-D8379794B11AQ42234608-7C6AB56F-239A-4D69-B815-28DCC6B4D07DQ42330818-9BC41CBC-F108-40EB-BCF8-7A577ABA3B58Q42361268-EB2D0D0E-7F62-4520-B0A2-C0963FA861DCQ42364239-3A8A2FC9-B889-4BB2-8AA7-3053A541AD33Q42372836-4FEBA406-EB8F-44E1-B482-D66B33B73ADCQ44006947-05813464-0785-4F42-BECB-75BEC474E5BCQ45074664-5A04B24F-8495-4158-91D5-CDC7938361ECQ46379792-FF8CD608-DC78-4159-BCAD-44ECDDAEB4CDQ47336139-5B178D93-D6A3-47A0-A94D-DE0D98296AB4Q47353792-0E1386A0-3AAC-4C60-89D5-6B0B3415EBF7
P2860
Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Overview of proteasome inhibit ...... f ubiquitin-proteasome system.
@ast
Overview of proteasome inhibit ...... f ubiquitin-proteasome system.
@en
Overview of proteasome inhibit ...... f ubiquitin-proteasome system.
@nl
type
label
Overview of proteasome inhibit ...... f ubiquitin-proteasome system.
@ast
Overview of proteasome inhibit ...... f ubiquitin-proteasome system.
@en
Overview of proteasome inhibit ...... f ubiquitin-proteasome system.
@nl
prefLabel
Overview of proteasome inhibit ...... f ubiquitin-proteasome system.
@ast
Overview of proteasome inhibit ...... f ubiquitin-proteasome system.
@en
Overview of proteasome inhibit ...... f ubiquitin-proteasome system.
@nl
P2860
P1476
Overview of proteasome inhibit ...... f ubiquitin-proteasome system.
@en
P2093
Jeffrey A Zonder
Q Ping Dou
P2860
P304
P356
10.2174/1568009614666140804154511
P577
2014-01-01T00:00:00Z